Neuberger Berman Group LLC lowered its position in shares of Bio-Techne Corp (NASDAQ:TECH) by 2.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,782,991 shares of the biotechnology company’s stock after selling 52,892 shares during the period. Neuberger Berman Group LLC owned about 4.76% of Bio-Techne worth $215,546,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Bio-Techne by 12.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,456 shares of the biotechnology company’s stock worth $171,000 after purchasing an additional 163 shares in the last quarter. Zions Bancorporation acquired a new stake in shares of Bio-Techne during the third quarter worth about $178,000. Flinton Capital Management LLC increased its position in shares of Bio-Techne by 84.8% during the second quarter. Flinton Capital Management LLC now owns 1,952 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 896 shares in the last quarter. Turner Investments LLC acquired a new position in Bio-Techne in the 3rd quarter valued at about $242,000. Finally, Koch Industries Inc. acquired a new position in Bio-Techne in the 2nd quarter valued at about $286,000. Institutional investors and hedge funds own 97.03% of the company’s stock.

Bio-Techne Corp (NASDAQ:TECH) opened at $127.32 on Wednesday. The stock has a market capitalization of $4,770.00, a PE ratio of 37.11, a P/E/G ratio of 3.21 and a beta of 0.75. Bio-Techne Corp has a 52-week low of $95.68 and a 52-week high of $136.39. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.87 and a quick ratio of 2.25.

Bio-Techne (NASDAQ:TECH) last released its earnings results on Tuesday, October 31st. The biotechnology company reported $0.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.08. Bio-Techne had a return on equity of 14.11% and a net margin of 12.54%. The company had revenue of $144.61 million for the quarter, compared to analysts’ expectations of $142.37 million. During the same quarter in the previous year, the firm posted $0.84 EPS. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. equities analysts expect that Bio-Techne Corp will post 3.76 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, November 24th. Shareholders of record on Friday, November 10th were given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 1.01%. The ex-dividend date was Thursday, November 9th. Bio-Techne’s payout ratio is 63.68%.

In other Bio-Techne news, Director Robert V. Baumgartner sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $130.18, for a total transaction of $650,900.00. Following the transaction, the director now owns 12,712 shares in the company, valued at approximately $1,654,848.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.40% of the company’s stock.

Several brokerages recently issued reports on TECH. BidaskClub cut Bio-Techne from a “buy” rating to a “hold” rating in a research report on Tuesday, December 5th. Zacks Investment Research upgraded Bio-Techne from a “hold” rating to a “buy” rating and set a $143.00 price target on the stock in a research report on Saturday, November 4th. Deutsche Bank set a $132.00 price target on Bio-Techne and gave the company a “buy” rating in a research report on Wednesday, August 30th. Leerink Swann restated a “buy” rating on shares of Bio-Techne in a research report on Tuesday, December 5th. Finally, Citigroup restated a “buy” rating and issued a $115.00 price target (down previously from $125.00) on shares of Bio-Techne in a research report on Tuesday, October 24th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $134.33.

WARNING: “Bio-Techne Corp (TECH) Shares Sold by Neuberger Berman Group LLC” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/13/bio-techne-corp-tech-shares-sold-by-neuberger-berman-group-llc.html.

About Bio-Techne

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH).

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Stock Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related stocks with our FREE daily email newsletter.